Skip to search formSkip to main contentSkip to account menu

VTX-2337

Known as: TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337 
A small-molecule Toll-like receptor 8 (TLR8) agonist with potential immunostimulating and antineoplastic activities. TLR8 agonist VTX-2337 binds to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Toll-like receptors (TLRs) are nucleic acid–sensing receptors and have been implicated in mediating pain and itch. Here we report… 
Highly Cited
2016
Highly Cited
2016
Purpose: As Toll-like receptors (TLR) are key mediators of immune responses, TLR agonists may be important for augmenting the… 
2016
2016
VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an… 
2015
2015
Purpose: Immunotherapy as a treatment for cancer holds the promise of complete and durable tumor remission, yet the… 
2014
2014
Purpose: This phase I, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD… 
Highly Cited
2013
Highly Cited
2013
BackgroundCetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody that prolongs survival in the… 
Highly Cited
2011
Highly Cited
2011
Purpose: We aim to characterize VTX-2337, a novel Toll-like receptor (TLR) 8 agonist in clinical development, and investigate its… 
2011
2011
2537 Background: Toll-like receptors (TLRs) have emerged as attractive targets for anti-cancer immunotherapies. VTX-2337 is a…